登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由广州医科大学附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05060796,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
18 Years to 75 Years, Histologically or cytologically confirmed Routine treatment of patients with advanced non-small cell lung cancer(Including TKI treatment failure patients);
入选标准第 2 条
Pathological results suggest that CXCL13 factor positive rate ≥ 10 %;
入选标准第 4 条
Screening of patients who had received other research drugs within 30 days before infusion;
排除标准第 5 条
Patients with central nervous system metastasis (after cerebral metastasis treatment is stable for more than 4 weeks and patients with asymptomatic brain metastasis do not need treatment), pericardial metastasis accompanied by a large amount of pericardial effusion;
排除标准第 12 条
The Eastern oncology group strength status score (ECOG) was 0-1;
入选标准第 7 条
After the signature of the informed consent and prior to the collection of a single nuclear cell, the immuno- histochemical test must determine that the expression of EGFR in the tumor site of the patient reaches the positive standard and the score is 2 + or more;
入选标准第 3 条
Women of childbearing age and all male subjects must agree to use effective contraceptive methods for at least 52 weeks after EGFR CAR-T infusion, and until two consecutive PCR tests show that CAR-T cells are no longer present in the body.
入选标准第 12 条
Patients who had undergone antitumor chemotherapy other than lymphocyte clearance chemotherapy within 14 days before the EGFR CAR-T infusion;
排除标准第 4 条
According to RECIST 1.1. The patient has at least one tumor lesion that can be measured (Results available within one month prior to screening period);
入选标准第 5 条
Patients with active hepatitis B: HBVDNA >1000 cps/ml;
排除标准第 7 条
Patients with HIV antibody, hepatitis C antibody, syphilis spirocyte positive;
排除标准第 8 条
Pregnant or lactating women;
排除标准第 14 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05060796,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
All subjects or legal guardians must sign the informed consent form approved by the ethics committee in writing before starting any screening procedure; 18 Years to 75 Years, Histologically or cytologically confirmed Routine treatment of patients with advanced non-small cell lung cancer(Including TKI treatment failure patients); After the signature of the informed consent and prior to the collection of a single nuclear cell, the immuno- histochemical test must determine that the expression of EGFR in the tumor site of the patient reaches the positive standard and the score is 2 + or more; Pathological results suggest that CXCL13 factor positive rate ≥ 10 %; According to RECIST 1.1. The patient has at least one tumor lesion that can be measured (Results available within one month prior to screening period); Expected survival time ≥ 12 weeks; The Eastern oncology group strength status score (ECOG) was 0-1; Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: Serum creatinine≤ 1.6 mg/ml or the creatinine clearance ≥ 40 ml/min/1.73m. Total bilirubin < 1.5 times upper limits of normal; The hemodynamics determined by echocardiography or multichannel radionuclide angiography(MUGA) are stable and the left ventricular ejection fraction (LVEF)≥50%; Have sufficient bone marrow reserves (subjects can meet this requirement through blood transfusion), defined as: The number of white blood cells should not be less than 2 × 10\^9/L;Platelet≥100 x 10\^9/L; Hemoglobin ≥100 g/L; If the patient uses the following drugs, the following conditions must be met: Women of childbearing age and all male subjects must agree to use effective contraceptive methods for at least 52 weeks after EGFR CAR-T infusion, and until two consecutive PCR tests show that CAR-T cells are no longer present in the body.排除标准:Exclusion Criteria:
Patients who have previously received any gene therapy product treatment, including CAR-T treatment; Patients with uncontrolled hypertension (> 160/95), unstable coronary artery disease confirmed by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure(>New York Heart Association Class II) or myocardial infarction within 6 months before cell infusion; Patients with severe liver and kidney dysfunction or consciousness disorders; Patients who had undergone antitumor chemotherapy other than lymphocyte clearance chemotherapy within 14 days before the EGFR CAR-T infusion; Screening of patients who had received other research drugs within 30 days before infusion; Patients undergoing radiotherapy and TKI treatment within 2 weeks before infusion ; Patients with active hepatitis B: HBVDNA >1000 cps/ml; Patients with HIV antibody, hepatitis C antibody, syphilis spirocyte positive; Patients with The sputum smear and tuberculosis infection T cell test positive; Patients with Interstitial lung disease or pneumonia; Patients with acute life-threatening bacteria, viruses or fungal infections that have not yet been controlled(for example, before transfusion ≤ 72 hours of blood culture positive); Patients with central nervous system metastasis (after cerebral metastasis treatment is stable for more than 4 weeks and patients with asymptomatic brain metastasis do not need treatment), pericardial metastasis accompanied by a large amount of pericardial effusion; Patients with a previous or concurrent second tumor, with the following exceptions: Pregnant or lactating women; Patients with history of T cell tumors or present with the disease. Having autoimmune or inflammatory disorders of active nerves (such as Guillian-Barre syndrome, amyotrophic lateral sclerosis); The researchers believe that other circumstances such as compliance should not be involved in this clinical trial.
引自 ClinicalTrials.gov, NCT05060796, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05060796,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。